FOR IMMEDIATE RELEASE – Feb. 23, 2022
CPR Therapeutics Inc. announced today that the company has received a U.S. patent for another component of technology that underlies its multimodal cardiopulmonary resuscitation (CPR) system: INCORPORATION OF THE ELECTRODES FOR DEFIBRILLATION INTO THE PATIENT-FACING COMPONENTS OF AUTOMATED CARDIOPULMONARY RESUSCITATION SYSTEMS (US11,253,713)
CPR Therapeutics Inc. is developing the first advanced technology automated CPR device that integrates and synchronizes multiple innovations into a single system that can be easily applied under emergency conditions. This multimodal CPR cannot be performed by humans, and significantly increases blood flow to the heart and brain while enhancing electrical countershock. The increased blood flow and more effective countershock both contribute to better patient outcomes in cardiac arrest, the leading single killer in the US and many other countries.
Norman Paradis, MD, CPR Therapeutics CEO announced: “This is a significant addition to our strong intellectual property portfolio. Already in place is our foundational patent on multimodal CPR, and now we have received one for integration and optimization of defibrillation.”
Henry Halperin, MD, the Company’s Chief Scientific Officer and a Professor of Medicine, Radiology and Biomedical Engineering, Johns Hopkins University highlighted: “Even most clinicians are not aware that when we switched from defibrillation paddles to adhesive gel pads, we lost the ability to optimize the countershock by pushing on the electrodes. The CPR-T System ™ will recover that lost efficacy by integrating CPR and defibrillation. We will optimize all the components that increase the odds of successful countershock.”
Karl Kern, MD, a Professor of Cardiology at the University of Arizona and renowned CPR researcher further explained: “Currently, paramedics stop chest compressions to shock patients, which drops blood flow to brain and heart to essentially zero. I’m excited that the CPR Therapeutics device will not only eliminate the interruptions, but it will also push on the gel pads and adjust ventilation – that combination should really improve the odds of restoring circulation after countershock.”
Lastly, Dr. Paradis added: “This is major milestone for our company. This patent protects multiple additional enhancements to efficacy that we intend to incorporate into the CPR-T System ™. We are pleased that the USPTO has allowed it.”
CPR Therapeutics Inc.
CPR Therapeutics Inc. is developing the first advanced technology automated cardiopulmonary resuscitation (CPR) system that integrates and synchronizes multiple technological innovations into a single system that can be easily applied under emergency conditions. It will enhance blood flow and the efficacy of electrical countershock in ways previously only available in laboratory settings. This system will, for the first time, demonstrate clinically significant improved survival. Sudden cardiac arrest may be the largest single cause of death and years of lost life in Western countries. Improving the outcome of patients after cardiac arrest is one of the great unmet medical needs.
Each year over 300,000 deaths occur following sudden cardiac arrest in the U.S. alone. Fifty years after the first description of modern cardiopulmonary resuscitation (CPR) survival is below 10%, and the standard-of-care for these patients remains chest compressions performed by rescuers with their hands. [email protected]
DISCLAIMER: The information provided pertaining to CPR Therapeutics Inc. (“CPR-T” or the “Company”), its business assets, strategy and operations is for general informational purposes only and is not a formal offer to sell or a solicitation of an offer to buy any securities, options, futures, or other derivatives related to securities in any jurisdiction and its content is not prescribed by securities laws. Information contained in this presentation should not be relied upon as advice to buy or sell or hold such securities or as an offer to sell such securities. This presentation does not take into account nor does it provide any tax, legal or investment advice or opinion regarding the specific investment objectives or financial situation of any person. While the information in this presentation is believed to be accurate and reliable, CPR-T and its agents, advisors, directors, officers, employees, and shareholders make no representation or warranties, expressed or implied, as to the accuracy of such information and CPR-T expressly disclaims any and all liability that may be based on such information or errors or omissions thereof. CPR-T reserves the right to amend or replace the information contained herein, in part or entirely, at any time, and undertakes no obligation to provide the recipient with access to the amended information or to notify the recipient thereof.